Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells

Fig. 1

Identification of integrin β3 as a kallistatin-binding protein. a The pull-down assay with the recombinant human kallistatin. The membrane proteins of NCI-H446 cell were pulled down by recombinant human kallistatin and subjected to immunoblotting with antibody anti-integrinβ3 (upper panel) and anti-kallistatin, respectively (lower panel). The membrane proteins incubated with Ni–NTA alone were used as control. b Immunoprecipitation of membrane proteins of NCI-H446 cell with anti-kallistatin antibody followed by immunoblotting against integrin β3 and kallistatin, respectively. The extracts of NCI-H446 cells treated without kallistatin were immunoprecipitatedas control. Co-immunoprecipitation sample without treated with Protein A-Sepharose were used to immunoblotting as input. c Immunoprecipitation of membrane proteins of NCI-H446 cell with anti-Integrin β3 antibody followed by immunoblotting against integrin β3 and kallistatin. The extracts of NCI-H446 cells treated without kallistatin were immunoprecipitated as control. Co-immunoprecipitation samples without treated with Protein A-Sepharose were used to immunoblotting as input

Back to article page